Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.

Park MC, Matsuno H, Kim J, Park SH, Lee SH, Park YB, Lee YJ, Lee SI, Park W, Sheen DH, Choe JY, Choi CB, Hong SJ, Suh CH, Lee SS, Cha HS, Yoo B, Hur JW, Kim GT, Yoo WH, Baek HJ, Shin K, Shim SC, Yang HI, Kim HA, Park KS, Choi IA, Lee J, Tomomitsu M, Shin S, Lee J, Song YW.

Open source

DOI: 10.1186/s13075-019-1910-2
Published: 2019-05-21
Container: Arthritis Res Ther
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13075-019-1910-2,
  title = {Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.},
  author = {Park MC and  Matsuno H and  Kim J and  Park SH and  Lee SH and  Park YB and  Lee YJ and  Lee SI and  Park W and  Sheen DH and  Choe JY and  Choi CB and  Hong SJ and  Suh CH and  Lee SS and  Cha HS and  Yoo B and  Hur JW and  Kim GT and  Yoo WH and  Baek HJ and  Shin K and  Shim SC and  Yang HI and  Kim HA and  Park KS and  Choi IA and  Lee J and  Tomomitsu M and  Shin S and  Lee J and  Song YW.},
  year = {2019},
  journal = {Arthritis Res Ther},
  doi = {10.1186/s13075-019-1910-2},
  url = {https://doi.org/10.1186/s13075-019-1910-2}
}

RIS

TY  - JOUR
TI  - Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
AU  - Park MC
AU  -  Matsuno H
AU  -  Kim J
AU  -  Park SH
AU  -  Lee SH
AU  -  Park YB
AU  -  Lee YJ
AU  -  Lee SI
AU  -  Park W
AU  -  Sheen DH
AU  -  Choe JY
AU  -  Choi CB
AU  -  Hong SJ
AU  -  Suh CH
AU  -  Lee SS
AU  -  Cha HS
AU  -  Yoo B
AU  -  Hur JW
AU  -  Kim GT
AU  -  Yoo WH
AU  -  Baek HJ
AU  -  Shin K
AU  -  Shim SC
AU  -  Yang HI
AU  -  Kim HA
AU  -  Park KS
AU  -  Choi IA
AU  -  Lee J
AU  -  Tomomitsu M
AU  -  Shin S
AU  -  Lee J
AU  -  Song YW.
PY  - 2019
JO  - Arthritis Res Ther
DO  - 10.1186/s13075-019-1910-2
UR  - https://doi.org/10.1186/s13075-019-1910-2
ER  -

APA

MC, P., H, M., J, K., SH, P., SH, L., YB, P., YJ, L., SI, L., W, P., DH, S., JY, C., CB, C., SJ, H., CH, S., SS, L., HS, C., B, Y., JW, H., GT, K., WH, Y., HJ, B., K, S., SC, S., HI, Y., HA, K., KS, P., IA, C., J, L., M, T., S, S., J, L., & YW., S. (2019). Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.. Arthritis Res Ther. https://doi.org/10.1186/s13075-019-1910-2

Source records

europe-pmc · retrieved 2026-09-27T15:29:54.015Z